ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO769

Regulation of Edn1 by Its Antisense Long Non-Coding RNA, Edn1-AS

Session Information

  • Hypertension and CVD: Mechanisms
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Hypertension and CVD

  • 1503 Hypertension and CVD: Mechanisms


  • Juffre, Alexandria, University of Florida, Gainesville, Florida, United States
  • Douma, Lauren G., University of Florida, Gainesville, Florida, United States
  • Wingo, Charles S., University of Florida, Gainesville, Florida, United States
  • Gumz, Michelle L., University of Florida, Gainesville, Florida, United States

Group or Team Name

  • Gumz Laboratory

The peptide hormone endothelin-1 (ET-1) decreases renal sodium reabsorption by inhibiting epithelial sodium channel (ENaC) activity. Dysfunctional regulation of sodium handling can cause hypertension and ET-1 is a therapeutic target. We discovered a long non-coding RNA (lncRNA), Edn1-AS, which is antisense to the Edn1 mRNA. Using CRISPR-modified human proximal tubule cells (HK-2), we previously found that cis over-expression of Edn1-AS (expressed from the same locus as Edn1) resulted in increased ET-1 levels in cultured human proximal tubule cells (HK-2). The goal of this study was to test the effect of trans-overexpression of Edn1-AS (from an exogenous DNA construct) on Edn1 expression. Based on our previous results, we hypothesized that trans over-expressing Edn1-AS in collecting duct cells would increase ET-1 mRNA expression.


Inducible Edn1-AS overexpressing IMCD-3 and mpkCCD cells were generated using Tet-ONE systems (Takara Clontech), which increases Edn1-AS expression after treatment with doxycycline. Edn1-AS lncRNA and Edn1 mRNA levels were determined by strand-specific RT-PCR or qPCR.


Similarly to cis over-expression in HK-2 cells, trans over-expression of Edn1-AS in IMCD-3 and mpkCCD cells showed increased Edn1 levels (n=3, p < 0.05 by unpaired t-test).


Consistent with our previous results in HK-2 cells, increased Edn1 expression was observed in Edn1-AS overexpressing IMCD-3 and mpkCCD cells. These data suggest that Edn1-AS is a positive regulator of Edn1, regardless of whether Edn1-AS is over-expressed in a cis or trans manner. Subsequent studies will seek to determine the mechanism of action of Edn1-AS on Edn1 expression which may involve chromatin remodeling. Future investigation of Edn1-AS's regulation of Edn1 could lead to the identification of novel therapeutic targets for treatment of hypertension.


  • NIDDK Support